Viking Therapeutics is a mid-clinical stage biotech company focused on development of therapeutics for endocrinological and orphan diseases near term. The company currently has two lead products in development: 1) VK5211, a non-steroidal selective androgen receptor modulator (SARM) that VKTX is starting post hip fracture surgery rehabilitation Phase II study in 3Q15 with top-line results expected in 2Q16; and 2) a thyroid β agonist, either VK0214 or VK2809, to be used as a potential treatment for X-linked adrenoleukodystrophy (X-ALD) with adrenomyeloneuropathy (AMN) subtype. A Phase I study is scheduled to start in 1Q16 with top-line results expected in mid- to 2H16. In addition, VKTX also has multiple clinical assets to be further developed once the company obtains more financial support. These assets include: 1) VK2809 in dyslipidemias, for which it has already exhibited positive results from a Phase Ib trial, and NASH; 2) VK0612, a Phase IIb-ready drug candidate for type 2 diabetes) 3) an EPO receptor (EPOR) agonist program in pre-clinical development as a potential treatment of anemia; and 4) a diacylglycerol acyltransferase-1 (DGAT-1) inhibitor program, which is pre-clinical as a potential treatment of lipid disorders such as obesity and dyslipidemia.